Effect of cilostazol on the ventricular escape rate and neurohumoral factors in patients with third-degree atrioventricular block

Chest

Volumn 123, Issue 4, 2003, Pages 1161-1169

  Kodama Takahashi, Koji ^a,b   Kurata, Akira ^a   Ohshima, Kiyotaka ^a   Yamamoto, Kozo ^a   Uemura, Shigeki ^a   Watanabe, Seiichiro ^a   Iwata, Takeru ^a  

^a Yawatahama General Hospital   (Japan)

^b Yawatahama General Hospital   (Japan)

Author keywords

Cilostazol; Phosphodiesterase inhibitor; Plasma natriuretic peptide; Third degree atrioventricular block

Indexed keywords

ANTITHROMBOCYTIC AGENT; ATRIAL NATRIURETIC FACTOR; CILOSTAZOL; PHOSPHODIESTERASE INHIBITOR;

ADAMS STOKES ATTACK; ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BLEEDING TIME; CLINICAL ARTICLE; ELECTROCARDIOGRAPHY MONITORING; ENZYME INHIBITION; EXTRASYSTOLE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PURKINJE CELL; SICK SINUS SYNDROME; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

EID: 0037389193     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.123.4.1161     Document Type: Article

References (18)

1. Okuda Y, Kimura Y, Yamashita K. Cilostazol. Cardiovasc Drug Rev 1993; 11:451-465
2. Umekawa H, Tanaka T, Kimura Y, et al. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography. Biochem Pharmacol 1984; 33:3339-3344
3. Shintani S, Watanabe K, Kawamura K, et al. General pharmacological properties of cilostazol, a new antithrombotic drug: Part II. Effect on the peripheral organs. Arzneimittelforschung 1985; 35:1163-1172
4. Atarashi H, Endoh Y, Saitoh H, et al. Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias. J Cardiovasc Pharmacol 1998; 31:534-539
5. Baratto MT, Berti S, Clerico A, et al. Atrial natriuretic peptide during different pacing modes in a comparison with hemodynamic changes. Pacing Clin Electrophysiol 1990; 13:432-442
6. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55:613-618
7. Gregoratos G, Cheitlin MD, Conill A, et al. ACC/AHA guidelines for implantation of cardiac pacemakers and anti-arrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol 1998; 31:1175-1209
8. Olgin JE, Zipes DP. Specific arrhythmias: diagnosis and treatment. In: Braunwald E, Zipes D, Libby P, eds. Heart disease: a textbook of cardiovascular medicine. 6th ed. Philadelphia, PA: WB Saunders, 2001; 815-889
9. Hynes JK, Holmes DR, Harrison CE. Five-year experience with temporary pacemaker therapy in the coronary care unit. Mayo Clin Proc 1983; 58:122-126
10. Tsutui M, Shimokawa H, Higuchi S, et al. Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angiography. Jpn Circ J 1996; 60:207-215
11. Park SW, Lee CW, Kim HS, et al. Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 1999; 84:511-514
12. Yoon YS, Shim WH, Lee DH, et al. Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Am J Cardiol 1999; 84:1375-1380
13. Niki T, Mori H. Phase I study of cilostazol: safety evaluation at increasing single doses in healthy volunteers. Arzneimittelforschung 1985; 35:1173-1185
14. Akiyama H, Kudo S, Shimizu T. The absorption, distribution and excretion of a new antithrombotic and vasodilatating agent, cilostazol, in rat, rabbit, dog and man. Arzneimittelforschung 1985; 35:1124-1132
15. La Villa G, Padeletti L, Lazzeri C, et al. Plasma levels of natriuretic peptides during ventricular pacing in patients with a dual chamber pacemaker. Pacing Clin Electrophysiol 1994; 17:953-958
16. Iida T, Hirata Y, Takemura N, et al. Brain natriuretic peptide is cosecreted with atrial natriuretic peptide from porcine cardiocytes. FEBS Lett 1990; 260:98-100
17. Vardas PE, Travill CM, Williams TDM, et al. Effect of dual chamber paring on raised plasma atrial natriuretic peptide concentrations in complete atrioventricular block. BMJ 1988; 296:94
18. Weil J, Lang RE, Suttmann H, et al. Concomitant increase in plasma atrial natriuretic peptide and cyclic GMP during volume loading. Klin Wochenschr 1985; 63:1265-1268